A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor Effect.
Wen X, Shi C, Zeng X, Zhao L, Yao L, Liu Z, Feng L, Zhang D, Huang J, Li Y, Lin Q, Chen H, Zhuang R, Chen X, Zhang X, Guo Z.
Wen X, et al. Among authors: huang j.
Clin Cancer Res. 2022 Jul 1;28(13):2923-2937. doi: 10.1158/1078-0432.CCR-22-0159.
Clin Cancer Res. 2022.
PMID: 35320358